Bukwang's Performance Declines Over 2.5 Years Under OCI: Will Q3 Bring a Turnaround?
It's been two and a half years since OCI became the largest shareholder of Bukwang Pharmaceutical, yet instead…
solid tumor treatment
1 개의 기사가 있습니다.